Patient, disease, and transplant characteristics
| . | Haplo-HSCT . |
|---|---|
| No. of patients | 2200 |
| Follow-up in mo, median (IQR) | 24 (23-25) |
| Age in y, median (range) | 56 (18-75) |
| Gender, n (%) | |
| Male | 1314 (60) |
| Female | 886 (40) |
| CMV serologic status, n (%) | |
| Negative | 1656 (75) |
| Positive | 544 (25) |
| Karnofsky score at transplant, n (%) | |
| <90 | 611 (29) |
| ≥90 | 1489 (71) |
| Missing | 100 |
| HCT-CI, n (%) | |
| 0 | 1090 (50) |
| 1-2 | 545 (25) |
| ≥3 | 565 (25) |
| Cytogenetic risk, n (%) | |
| Standard | 161 (7) |
| Intermediate | 1451 (66) |
| Adverse | 588 (27) |
| FLT3-ITD, n (%) | |
| Absent | 871 (66) |
| Present | 417 (32) |
| Missing | 912 |
| NPM1, n (%) | |
| Absent | 772 (61) |
| Present | 487 (39) |
| Missing | 941 |
| Disease status at transplant, n (%) | |
| CR1 | 1331 (61) |
| CR2 | 393 (18) |
| CR ≥ 3 | 18 (1) |
| Relapsed/refractory disease | 458 (21) |
| Conditioning intensity, n (%) | |
| Myeloablative | 954 (43) |
| Reduced intensity | 1246 (57) |
| Conditioning regimen, n (%) | |
| Chemotherapy-based | 1801 (82) |
| TBI-based | 399 (18) |
| In vivo T-cell depletion, n (%) | |
| No | 2012 (92) |
| Yes | 188 (9) |
| GVHD prophylaxis, n (%) | |
| PTCy + calcineurin inhibitor + MMF | 1927 (86) |
| PTCy + sirolimus + MMF | 77 (3.5) |
| PTCy + calcineurin inhibitor | 72 (3.3) |
| PTCy + calcineurin inhibitor + MTX | 53 (2.6) |
| PTCy + MMF | 45 (2) |
| Other | 26 (1.2) |
| . | Haplo-HSCT . |
|---|---|
| No. of patients | 2200 |
| Follow-up in mo, median (IQR) | 24 (23-25) |
| Age in y, median (range) | 56 (18-75) |
| Gender, n (%) | |
| Male | 1314 (60) |
| Female | 886 (40) |
| CMV serologic status, n (%) | |
| Negative | 1656 (75) |
| Positive | 544 (25) |
| Karnofsky score at transplant, n (%) | |
| <90 | 611 (29) |
| ≥90 | 1489 (71) |
| Missing | 100 |
| HCT-CI, n (%) | |
| 0 | 1090 (50) |
| 1-2 | 545 (25) |
| ≥3 | 565 (25) |
| Cytogenetic risk, n (%) | |
| Standard | 161 (7) |
| Intermediate | 1451 (66) |
| Adverse | 588 (27) |
| FLT3-ITD, n (%) | |
| Absent | 871 (66) |
| Present | 417 (32) |
| Missing | 912 |
| NPM1, n (%) | |
| Absent | 772 (61) |
| Present | 487 (39) |
| Missing | 941 |
| Disease status at transplant, n (%) | |
| CR1 | 1331 (61) |
| CR2 | 393 (18) |
| CR ≥ 3 | 18 (1) |
| Relapsed/refractory disease | 458 (21) |
| Conditioning intensity, n (%) | |
| Myeloablative | 954 (43) |
| Reduced intensity | 1246 (57) |
| Conditioning regimen, n (%) | |
| Chemotherapy-based | 1801 (82) |
| TBI-based | 399 (18) |
| In vivo T-cell depletion, n (%) | |
| No | 2012 (92) |
| Yes | 188 (9) |
| GVHD prophylaxis, n (%) | |
| PTCy + calcineurin inhibitor + MMF | 1927 (86) |
| PTCy + sirolimus + MMF | 77 (3.5) |
| PTCy + calcineurin inhibitor | 72 (3.3) |
| PTCy + calcineurin inhibitor + MTX | 53 (2.6) |
| PTCy + MMF | 45 (2) |
| Other | 26 (1.2) |
IQR, interquartile range; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation.